Kristina Savic

Kristina Savic

Auto-generated profile, based on publicly available information

Kristina Savic

University of Novi Sad, Faculty of Medicine Novi Sad

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Medicinski Pregled
Verified
Journal Article
Open access
PDF file
DKDunja Kokanov
Dunja Kokanov
TMTamara Maksimovic
Tamara Maksimovic
NSNemanja Stevanovic
Nemanja Stevanovic
SMSlobodan Maricic
Slobodan Maricic
SPSonja Lukac Pualic
Sonja Lukac Pualic
KSKristina Savic
Kristina Savic
Introduction. Ovarian cancer represents the deadliest gynecological malignancy. The aim of this study is to validate the predictive value of Cancer antigen-125 Elimination rate constant K score regarding progression-free survival among patients with Stage IIIc-IV high-grade serous ovarian cancer according to the International Federation of Gynecology and Obstetrics, treated with bevacizumab. Additionally, the study aims to determine the significance of a score in the assessment of progression-free survival in relation to operation status and disease stage. Material and Methods. The retrospective study was conducted at the Oncology Institute of Vojvodina and included 56 patients treated for high-grade serous ovarian cancer. The treatment protocol consisted of chemotherapy with paclitaxel and carboplatin, followed by bevacizumab maintenance therapy. The Cancer Antigen- 125 Elimination Rate Constant K score was calculated using three Cancer Antigen 125 tumor marker values. Based on this calculation, the score was dichotomized into favorabe (?1) and unfavorable (<1) groups. Results. The analysis of the score?s impact on progression-free survival revealed that patients with a score ?1 had longer mean survival time compared to a score <1 (19.4 vs 17.0 months). This difference was not statistically significant (p=0.549). The operation status in relation to a score was the only statistically significant factor with progression-free survival benefit (p=0.002). Conclusion. In our study, Cancer antigen- 125 Elimination rate constant K score did not emerge as a statistically significant prognostic factor for identifying patients most likely to benefit from bevacizumab. The operative status showed significant predictive value.